- Home
- DAWN vs SLNO Comparison
DAWN vs SLNO Comparison
Compare DAWN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | SLNO |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DAWN | SLNO |
|---|---|---|
| Price | $21.50 | $53.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $24.43 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.4M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.59 |
| Revenue | ★ $158,182,000.00 | $1,450,788.00 |
| Revenue This Year | $55.03 | $150.46 |
| Revenue Next Year | $28.12 | $50.37 |
| P/E Ratio | ★ N/A | $89.83 |
| Revenue Growth | 20.60 | ★ 138.82 |
| 52 Week Low | $5.64 | $29.43 |
| 52 Week High | $21.53 | $89.12 |
Technical Indicators
Market Signals| Indicator | DAWN | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 77.32 |
| Support Level | $10.30 | $48.91 |
| Resistance Level | N/A | $55.47 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.28 | -0.52 |
| Stochastic Oscillator | 90.91 | 100.00 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.